ascopubs.org

Cost-effectiveness analysis using a Markov model assessing the addition of bevacizumab to paclitaxel in HER2-negative metastatic breast cancer patients.

Patient-reported pain and other symptoms as prognostic factors for overall survival (OS) in a phase III clinical trial of patients with advanced breast cancer. This is an ASCO Meeting Abstract from ...
JSTOR Daily

A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for "glioblastoma ...

This is a preview. Log in through your library . Abstract Background Cost-effectiveness analyses of treatments for glioblastoma multiforme (GBM) have mostly used state transition Markov models with ...
JSTOR Daily

The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model

Purpose Adenoid hypertrophy (AH) is common among young children. Adenoid-based surgery and drug therapy could be applied for symptomatic AH patients, yet the treatment decision is difficult to make ...
ascopubs.org

Cost effectiveness of adjuvant pembrolizumab after nephrectomy for RCC: Insights for patient selection from a Markov model.

Efficacy of first-line combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS). A survey study of prevention and treatment patterns by academic ...
The American Journal of Managed Care

Biosimilars More Cost-Effective Than Leflunomide After Methotrexate Failure in RA

Biosimilar DMARDs offer cost-effective and improved outcomes over leflunomide for RA patients unresponsive to methotrexate. The study used a Markov model with data from 25,099 RA patients to simulate ...